NextCure

NXTC

Biotechnology · Healthcare

Price

$5.99

-0.18 (-2.92%)

Market Cap

$16.1M

Exchange

NASDAQ Global Select

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+23.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.3M (2021) → 2.8M (2025)

NextCure is a clinical-stage biotechnology company that discovers and develops new medicines to treat cancer and other serious diseases. It focuses on a field called immunomedicine, which means it tries to use the body's own immune system to fight illness. The company's main work involves finding proteins on immune cells that can be targeted with drugs to restore the immune system's ability to attack tumors.

NextCure makes no product revenue yet because its drugs are still being tested in clinical trials. The company is based in Beltsville, Maryland, and is funded primarily through cash reserves and equity offerings rather than sales. Its lead program has faced setbacks in clinical trials, which has significantly reduced its market value and raised questions about its path forward. The main risk is that the company must successfully advance at least one drug candidate through trials before its cash runs out, or it will need to raise more money or find a partner to survive.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+60.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$45M/ year

↑ Rising (+8% vs prior year)

R&D investment increasing — building for the future

Insider Activity

40.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$30M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

NextCure has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-31.9%

Weak — -31.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.18

Conservative — low debt load (0.18)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial